In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

LUCY Letby’s former boss thought that she was a “scapegoat” for the hospital’s failings and would be cleared without charge, a former chief executive has claimed. Letby, ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

Every year, 900,000 Americans are caught by surprise by the symptoms of a pulmonary embolism: a sudden shortness of breath, ...

The first hemophilia B patient at the Loma Linda University Health Hemophilia Treatment Center to receive Hympavzi is a ...

Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.

Already having been legalised in many European countries, alongside Canada and several states in the US, assisted dying seems to be slowly becoming a hallmark of the modern medical system. The choice ...